Logo image of BLND

BLEND LABS INC-A (BLND) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:BLND - US09352U1088 - Common Stock

3.04 USD
-0.01 (-0.33%)
Last: 12/29/2025, 8:04:00 PM
3.0201 USD
-0.02 (-0.65%)
After Hours: 12/29/2025, 8:04:00 PM
Fundamental Rating

3

BLND gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 276 industry peers in the Software industry. The financial health of BLND is average, but there are quite some concerns on its profitability. BLND is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

BLND had positive earnings in the past year.
BLND had a positive operating cash flow in the past year.
BLND had negative earnings in each of the past 5 years.
In the past 5 years BLND always reported negative operating cash flow.
BLND Yearly Net Income VS EBIT VS OCF VS FCFBLND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

BLND's Return On Assets of -12.79% is on the low side compared to the rest of the industry. BLND is outperformed by 67.75% of its industry peers.
BLND's Return On Equity of -17.03% is in line compared to the rest of the industry. BLND outperforms 42.39% of its industry peers.
Industry RankSector Rank
ROA -12.79%
ROE -17.03%
ROIC N/A
ROA(3y)-100.49%
ROA(5y)-70.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLND Yearly ROA, ROE, ROICBLND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

BLND has a Gross Margin (68.99%) which is comparable to the rest of the industry.
BLND's Gross Margin has declined in the last couple of years.
BLND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
BLND Yearly Profit, Operating, Gross MarginsBLND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

6

2. Health

2.1 Basic Checks

BLND does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLND has more shares outstanding than it did 1 year ago.
BLND has more shares outstanding than it did 5 years ago.
BLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BLND Yearly Shares OutstandingBLND Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
BLND Yearly Total Debt VS Total AssetsBLND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.60, we must say that BLND is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.60, BLND is not doing good in the industry: 68.12% of the companies in the same industry are doing better.
There is no outstanding debt for BLND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.6
ROIC/WACCN/A
WACC11.12%
BLND Yearly LT Debt VS Equity VS FCFBLND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.54 indicates that BLND has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.54, BLND is doing good in the industry, outperforming 69.20% of the companies in the same industry.
A Quick Ratio of 2.54 indicates that BLND has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.54, BLND is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.54
BLND Yearly Current Assets VS Current LiabilitesBLND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

5

3. Growth

3.1 Past

BLND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.88%, which is quite impressive.
Looking at the last year, BLND shows a very negative growth in Revenue. The Revenue has decreased by -15.41% in the last year.
Measured over the past years, BLND shows a very strong growth in Revenue. The Revenue has been growing by 26.16% on average per year.
EPS 1Y (TTM)105.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%190.12%
Revenue 1Y (TTM)-15.41%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%-27.28%

3.2 Future

The Earnings Per Share is expected to grow by 56.51% on average over the next years. This is a very strong growth
Based on estimates for the next years, BLND will show a small growth in Revenue. The Revenue will grow by 3.12% on average per year.
EPS Next Y141.44%
EPS Next 2Y72.92%
EPS Next 3Y56.51%
EPS Next 5YN/A
Revenue Next Year-24.11%
Revenue Next 2Y-4.65%
Revenue Next 3Y3.12%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BLND Yearly Revenue VS EstimatesBLND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
BLND Yearly EPS VS EstimatesBLND Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 304.00, which means the current valuation is very expensive for BLND.
Based on the Price/Earnings ratio, BLND is valued a bit more expensive than the industry average as 61.23% of the companies are valued more cheaply.
The average S&P500 Price/Earnings ratio is at 26.84. BLND is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 38.37, BLND can be considered very expensive at the moment.
BLND's Price/Forward Earnings is on the same level as the industry average.
BLND's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.40.
Industry RankSector Rank
PE 304
Fwd PE 38.37
BLND Price Earnings VS Forward Price EarningsBLND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLND Per share dataBLND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BLND's earnings are expected to grow with 56.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.15
PEG (5Y)N/A
EPS Next 2Y72.92%
EPS Next 3Y56.51%

0

5. Dividend

5.1 Amount

BLND does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

BLEND LABS INC-A

NYSE:BLND (12/29/2025, 8:04:00 PM)

After market: 3.0201 -0.02 (-0.65%)

3.04

-0.01 (-0.33%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)N/A N/A
Inst Owners69.89%
Inst Owner Change-2.58%
Ins Owners3.77%
Ins Owner Change1.95%
Market Cap789.64M
Revenue(TTM)132.56M
Net Income(TTM)-24.24M
Analysts80
Price Target4.29 (41.12%)
Short Float %5.95%
Short Ratio3.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-100%
Min EPS beat(2)-100%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-19.36%
Min EPS beat(4)-100%
Max EPS beat(4)222.55%
EPS beat(8)4
Avg EPS beat(8)12%
EPS beat(12)7
Avg EPS beat(12)10.39%
EPS beat(16)10
Avg EPS beat(16)7.49%
Revenue beat(2)0
Avg Revenue beat(2)-2.49%
Min Revenue beat(2)-3.21%
Max Revenue beat(2)-1.77%
Revenue beat(4)0
Avg Revenue beat(4)-9.39%
Min Revenue beat(4)-30.67%
Max Revenue beat(4)-1.77%
Revenue beat(8)2
Avg Revenue beat(8)-4.38%
Revenue beat(12)4
Avg Revenue beat(12)-2.24%
Revenue beat(16)7
Avg Revenue beat(16)-0.2%
PT rev (1m)-9.95%
PT rev (3m)-13.2%
EPS NQ rev (1m)-32.13%
EPS NQ rev (3m)-2.27%
EPS NY rev (1m)-7.14%
EPS NY rev (3m)-13.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.88%
Revenue NY rev (1m)-1.41%
Revenue NY rev (3m)-2.12%
Valuation
Industry RankSector Rank
PE 304
Fwd PE 38.37
P/S 5.96
P/FCF N/A
P/OCF 132.8
P/B 5.55
P/tB 5.55
EV/EBITDA N/A
EPS(TTM)0.01
EY0.33%
EPS(NY)0.08
Fwd EY2.61%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0.02
OCFY0.75%
SpS0.51
BVpS0.55
TBVpS0.55
PEG (NY)2.15
PEG (5Y)N/A
Graham Number0.35
Profitability
Industry RankSector Rank
ROA -12.79%
ROE -17.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.99%
FCFM N/A
ROA(3y)-100.49%
ROA(5y)-70.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 511.77%
Cap/Sales 9.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.54
Altman-Z 0.6
F-Score6
WACC11.12%
ROIC/WACCN/A
Cap/Depr(3y)157.7%
Cap/Depr(5y)104.5%
Cap/Sales(3y)2.44%
Cap/Sales(5y)1.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%190.12%
EPS Next Y141.44%
EPS Next 2Y72.92%
EPS Next 3Y56.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.41%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%-27.28%
Revenue Next Year-24.11%
Revenue Next 2Y-4.65%
Revenue Next 3Y3.12%
Revenue Next 5YN/A
EBIT growth 1Y70.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year202.8%
EBIT Next 3Y72.9%
EBIT Next 5YN/A
FCF growth 1Y95.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y103.86%
OCF growth 3YN/A
OCF growth 5YN/A

BLEND LABS INC-A / BLND FAQ

What is the fundamental rating for BLND stock?

ChartMill assigns a fundamental rating of 3 / 10 to BLND.


What is the valuation status for BLND stock?

ChartMill assigns a valuation rating of 1 / 10 to BLEND LABS INC-A (BLND). This can be considered as Overvalued.


How profitable is BLEND LABS INC-A (BLND) stock?

BLEND LABS INC-A (BLND) has a profitability rating of 1 / 10.


Can you provide the PE and PB ratios for BLND stock?

The Price/Earnings (PE) ratio for BLEND LABS INC-A (BLND) is 304 and the Price/Book (PB) ratio is 5.55.


What is the expected EPS growth for BLEND LABS INC-A (BLND) stock?

The Earnings per Share (EPS) of BLEND LABS INC-A (BLND) is expected to grow by 141.44% in the next year.